
Pei San Ang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1189544/publications.pdf Version: 2024-02-01



DEL SAN ANC

#	Article	IF	CITATIONS
1	Data mining spontaneous adverse drug event reports for safety signals in Singapore – a comparison of three different disproportionality measures. Expert Opinion on Drug Safety, 2016, 15, 583-590.	1.0	43
2	Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer. International Journal of Medical Informatics, 2019, 128, 62-70.	1.6	18
3	A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms. Drug Safety, 2017, 40, 517-530.	1.4	8
4	Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea. Healthcare Informatics Research, 2022, 28, 112-122.	1.0	7
5	Detecting Signals of Disproportionate Reporting from Singapore's Spontaneous Adverse Event Reporting System: An Application of the Sequential Probability Ratio Test. Drug Safety, 2017, 40, 703-713.	1.4	6
6	Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries. Pharmacoepidemiology and Drug Safety, 2018, 27, 87-94.	0.9	6
7	Towards Human–Machine Collaboration in Creating an Evaluation Corpus for Adverse Drug Events in Discharge Summaries of Electronic Medical Records. Big Data Research, 2016, 4, 37-43.	2.6	4
8	Comparison of laboratory threshold criteria in drugâ€induced liver injury detection algorithms for use in pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2020, 29, 1480-1488.	0.9	4
9	Quantitative data mining in signal detection: the Singapore experience. Expert Opinion on Drug Safety, 2020, 19, 633-639.	1.0	2
10	Augmenting Product Defect Surveillance Through Web Crawling and Machine Learning in Singapore. Drug Safety, 2021, 44, 939-948.	1.4	2
11	A risk classification model for prioritising the management of quality issues relating to substandard medicines in Singapore. Pharmacoepidemiology and Drug Safety, 2022, , .	0.9	1